BioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient's homes, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado.
Industry, Sector and Symbol
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Phone720-697-5200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$708.90 million
Profitability
Miscellaneous
Employees2,154
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
BioScrip (NASDAQ:BIOS) Frequently Asked Questions
What is BioScrip's stock symbol?
BioScrip trades on the NASDAQ under the ticker symbol "BIOS."
How were BioScrip's earnings last quarter?
BioScrip Inc (NASDAQ:BIOS) issued its quarterly earnings results on Friday, March, 15th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.11. The firm had revenue of $183.57 million for the quarter, compared to analyst estimates of $188.39 million. BioScrip's quarterly revenue was up .5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.03) EPS. View BioScrip's Earnings History.
When is BioScrip's next earnings date?
What price target have analysts set for BIOS?
4 Wall Street analysts have issued 1-year price objectives for BioScrip's shares. Their forecasts range from $2.51 to $10.00. On average, they expect BioScrip's stock price to reach $5.0025 in the next twelve months. This suggests a possible upside of 159.2% from the stock's current price. View Analyst Price Targets for BioScrip.
What is the consensus analysts' recommendation for BioScrip?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioScrip in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioScrip.
What are Wall Street analysts saying about BioScrip stock?
Here are some recent quotes from research analysts about BioScrip stock:
- 1. According to Zacks Investment Research, "In the last-reported quarter, BioScrip's revenues getting affected by the impact of higher core product mix, including the impact of contract changes with UnitedHealthcare worries us. However, we are encouraged by the company’s progress in the third quarter, courtesy of its new multi-faceted CORE plan to improve its financial position. The company also expects to earn core revenues at Home Solutions and witness continued core growth. The company also took certain rigorous steps to revitalize its sales force in the reported quarter. These developments should further drive business growth in 2018. Overall, BioScrip has outperformed its industry in the past six months." (1/3/2019)
- 2. Barrington Research analysts commented, "We continue to rate BIOS shares an OUTPERFORM and our price target is $4. We arrive at our price target by attaching a 14x multiple to our 2019 adjusted EBITDA estimate. We assume approximately $550 million in net debt (including pfd stock) 12 months from now. Company Description BioScrip, Inc. is a leading national provider of infusion and home healthcare management solutions. BioScrip partners with healthcare providers, including physicians, hospital systems, skilled nursing facilities, and with healthcare payors to provide patients better access to high quality, efficient post‐acute care services. BioScrip operates with a commitment to bring infusion therapy services into the home or alternate‐site settings." (10/5/2018)
Has BioScrip been receiving favorable news coverage?
News stories about BIOS stock have been trending somewhat positive on Friday, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioScrip earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an effect on the company's share price in the near term.
Who are some of BioScrip's key competitors?
What other stocks do shareholders of BioScrip own?
Who are BioScrip's key executives?
BioScrip's management team includes the folowing people:
- Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 54)
- Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)
- Ms. Harriet Booker, Sr. VP & COO (Age 52)
- Ms. Jody Kepler, Sr. VP, Chief Compliance Officer (Age 49)
- Mr. John McMahon, Chief Accounting Officer, VP & Controller (Age 54)
Who are BioScrip's major shareholders?
BioScrip's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Venor Capital Management LP (10.04%), BlackRock Inc. (7.66%), Gabelli Funds LLC (5.55%), FMR LLC (3.19%), D. E. Shaw & Co. Inc. (2.96%) and Diamond Hill Capital Management Inc. (2.34%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, Michael G Bronfein and Stephen Deitsch. View Institutional Ownership Trends for BioScrip.
Which institutional investors are selling BioScrip stock?
BIOS stock was sold by a variety of institutional investors in the last quarter, including Venor Capital Management LP, Gabelli Funds LLC, FMR LLC, Diamond Hill Capital Management Inc., Alta Fundamental Advisers LLC, D. E. Shaw & Co. Inc., Millennium Management LLC and Bank of America Corp DE. View Insider Buying and Selling for BioScrip.
Which institutional investors are buying BioScrip stock?
BIOS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Two Sigma Investments LP, Perritt Capital Management Inc., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Geode Capital Management LLC, Geode Capital Management LLC and MUFG Securities EMEA plc. Company insiders that have bought BioScrip stock in the last two years include Daniel E Greenleaf and Stephen Deitsch. View Insider Buying and Selling for BioScrip.
How do I buy shares of BioScrip?
Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioScrip's stock price today?
One share of BIOS stock can currently be purchased for approximately $1.93.
How big of a company is BioScrip?
BioScrip has a market capitalization of $247.33 million and generates $708.90 million in revenue each year. The company earns $-51,690,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. BioScrip employs 2,154 workers across the globe.
What is BioScrip's official website?
How can I contact BioScrip?
BioScrip's mailing address is 1600 BROADWAY SUITE 700, DENVER CO, 80202. The company can be reached via phone at 720-697-5200 or via email at [email protected]
MarketBeat Community Rating for BioScrip (NASDAQ BIOS)
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
